Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
NCT ID: NCT03604198
Last Updated: 2025-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
125 participants
INTERVENTIONAL
2018-05-07
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
NCT03697109
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
NCT02804750
Open-label Treatment in Cushing's Syndrome
NCT03621280
Treatment for Endogenous Cushing's Syndrome
NCT01838551
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
NCT03606408
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Once-daily dosing with relacorilant may continue for patients who receive clinical benefits (as judged by the Investigator) until relacorilant is commercially or otherwise available or the study is stopped by the Sponsor. A patient's dose may be maintained, reduced, or increased based on individual response and tolerability.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
relacorilant (CORT125134)
relacorilant
CORT125134 is supplied as capsules for oral dosing.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
relacorilant
CORT125134 is supplied as capsules for oral dosing.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* According to the Investigator's opinion will benefit from continuing treatment with relacorilant
Exclusion Criteria
* Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
* Has poorly controlled hypertension
* Has Stage ≥ 4 renal failure
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Corcept Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ying Ru, MD, PhD
Role: STUDY_DIRECTOR
Corcept Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 49
Phoenix, Arizona, United States
Site 35
Stanford, California, United States
Site 39
Torrance, California, United States
Site 50
Miami, Florida, United States
Site 10
Atlanta, Georgia, United States
Site 9
Chicago, Illinois, United States
Site 1
Indianapolis, Indiana, United States
Site 5
Metairie, Louisiana, United States
Site 27
Baltimore, Maryland, United States
Site 13
Fall River, Massachusetts, United States
Site 8
Ann Arbor, Michigan, United States
Site 36
Rochester, Minnesota, United States
Site 34
Jackson, Mississippi, United States
Site 3
St Louis, Missouri, United States
Site 55
Reno, Nevada, United States
Site 6
Albany, New York, United States
Site 24
New York, New York, United States
Site 4
Wilmington, North Carolina, United States
Site 43
Cleveland, Ohio, United States
Site 2
Pittsburgh, Pennsylvania, United States
Site 46
Pittsburgh, Pennsylvania, United States
Site 11
Dallas, Texas, United States
Site 7
El Paso, Texas, United States
Site 32
Fort Worth, Texas, United States
Site 12
Houston, Texas, United States
Site 14
Vienna, , Austria
Site 51
Nova Scotia, , Canada
Site 16
Munich, , Germany
Site 42
Würzburg, , Germany
Site 20
Ramat Gan, , Israel
Site 29
Tel Aviv, , Israel
Site 40
Ancona, , Italy
Site 44
Messina, , Italy
Site 25
Milan, , Italy
Site 21
Napoli, , Italy
Site 48
Padua, , Italy
Site 52
Torino, , Italy
Site 33
Rotterdam, , Netherlands
Site 47
Krakow, , Poland
Site 45
Lublin, , Poland
Site 37
Bucharest, , Romania
Site 31
Bucharest, , Romania
Site 28
Bucharest, , Romania
Site 53
Alicante, , Spain
Site 18
Girona, , Spain
Site 17
Madrid, , Spain
Site 38
Málaga, , Spain
Site 19
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CORT125134-452
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.